External Advisory Board

Grand MMTI –  External Advisory Board

The Grand MMTI's External Advisory Board (EAB) consists of internationally recognized myeloma clinicians and researchers. The SAB provides scientific and strategic guidance on the Grand MMTI clinical and research programs and provides insights on the most up-to-date advances in the treatment and diagnosis of multiple myeloma.

Constantine Mitsiades, MD, PhD
Instructor, Department of Medicine, Harvard Medical School
Instructor in Medicine, Medical Oncology, Dana-Farber Cancer Institute

Dr. Constantine Mitsiades is a physician/scientist at Dana-Farber Cancer Institute in which his research has led to the clinical development of novel therapeutics, including the FDA approved combination of proteasome inhibitors with anthracyclines. He has many years of experience in the field of multiple myleoma and the role of the tumor microenvironment.

P. Leif Bergsagel, MD
Grohne Professor of Therapeutics for Cancer Research
Consultant, Mayo Clinic Arizona,
Professor of Medicine, Mayo Clinic College of Medicine

Dr. Bergsagel is a Professor of Medicine for the Mayo Clinic College of Medicine, and a consultant in the Division of Hematology and Oncology, Department of Internal Medicine, at Mayo Clinic in Arizona. He received a B.Sc. degree and M.D. degree from the University of Toronto. He completed an internship in internal medicine and a residency at the University of Toronto Sunnybrook Medical Centre, as well as a residency at Stanford University Medical Center and completed a Fellowship program in Medical Oncology at the National Cancer Institute, Bethesda, MD, where he worked in the laboratory of Dr. Michael Kuehl for seven years. After working at Weill Cornell Medical College in New York City for eight years, he moved to Mayo Clinic Arizona in 2004. /p>

Dr. Bergsagel’s research interest focuses on molecular pathogenesis of multiple myeloma. Working together with his wife, Dr. Marta Chesi, he identified the recurrent chromosome translocations in multiple myeloma, a promiscuous array of mutations that activate the NFKB pathway, and developed a novel transgenic mouse model that faithfully reproduces the genetic, phenotypic, clinical and therapeutic features of human myeloma. An active investigator in many clinical trials, he has led efforts to develop targeted therapy for multiple myeloma, starting with targeting the t(4;14) chromosome translocation that he identified. /p>

Dr. Bergsagel has received numerous honors and awards during his training and career. He has recently been awarded the 2009 Robert A. Kyle Mayo Clinic Distinguished Investigator by Mayo Clinic Arizona, the 2010 Daniel E. Bergsagel Visiting Professor by the Ontario Cancer Institute, an award in honor of his father, also a myeloma researcher, the 2012 David A. Galton Lecturer, Hammersmith Hospital and the 2013 Bertha A. Bouroncle Lectureship, Ohio State University Medical Center

Marta Chesi, PhD
Associate Consultant II, Mayo Clinic Arizona
Assistant Professor of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine

Dr. Chesi is an Assistant Professor of Biochemistry and Molecular Biology for the Mayo Clinic College of Medicine, and an Associate Consultant II in the Division of Hematology and Oncology, Department of Internal Medicine, at Mayo Clinic in Arizona. She received a PhD in Biochemistry from the University of Milan, Italy. She enrolled in the Fogarty Fellowship program at the Genetics Branch, National Cancer Institute, Bethesda, MD, in the laboratory of Dr. Michael Kuehl for three years. In 1998 she moved to the Weill Cornell Medical College in New York City where she worked in the laboratory of Leif Bergsagel as Research Associate, Instructor of Medicine and then as Assistant Professor of Biochemistry in Medicine. In 2004 she moved to Mayo Clinic Arizona with Dr. Bergsagel.

 

Dr. Chesi’s shares her research effort with Dr. Bergsagel, aimed to the understanding of the molecular pathogenesis of multiple myeloma. Together, they discovered and characterized the recurrent chromosome translocations that are considered the primary transforming event in multiple myeloma and provide the basis for disease stratification. While they continue working together on the identification of myeloma progression events (e.g. NFKB activating mutations) and clonal heterogeneity, Dr. Chesi work has focused on the development and characterization of a novel transgenic mouse model, Vk*MYC, that reproduces the genetic, phenotypic, clinical and therapeutic features of myeloma. The remarkable faithfulness of the Vk*MYC mice to the human disease has led to the identification of MYC dysregulation as progression event from MGUS to myeloma. Dr. Chesi has shared the Vk*MYC mice with many investigators around the world in a collaborative effort to develop effective immunotherapy against myeloma.

Dr. Chesi has received numerous honors and awards during her career, including the Department of Medicine Investigator Award by the Michael Wolk Heart Foundation and several research award and travel grants by the Multiple Myeloma Research Foundation. She has been invited to present her work at numerous national and international academic institutions and she was the 2014 Else-Kroner Lecturer at the University of Wurzburg, Germany.

Mark Rolfe, PhD
President and CSO, Cleave Biosciences
Dr. Mark Rolfe has over 20 years of industry experience in oncology drug discovery and development and is a recognized expert in the field of protein homeostasis. Before joining Cleave Biosciences, he spent a year at CytomX Therapeutics as Chief Scientific Officer and a year at Facet Biotech in the same role as well as interim Chief Medical Officer until its successful acquisition by Abbott Laboratories. Prior to joining Facet, Dr. Rolfe served as Vice President, Oncology Discovery at Millennium Pharmaceuticals where his group progressed multiple novel drugs targeting protein homeostasis into development. At Millennium he also spent two years as the VELCADE® Discovery Leader, during which time the drug received a number of regulatory approvals. Prior experience includes research positions at Mitotix Inc. and Celltech Ltd.

Sergio Giralt, MD
Chief, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering
Dr. Sergio Giralt is an internationally recognized bone marrow transplantation expert. In 2010, he joined the Memorial Sloan-Kettering Cancer Center as Chief of the Adult Bone Marrow Transplant Service, following a 20-year-long career at the MD Anderson Cancer Center. Dr. Giralt received his medical degree from Universidad Central de Venezuela in Caracas, Venezuela, and completed his postgraduate internship at the University Hospital of Caracas.

Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt’s research focuses on improving treatments for older patients, particularly in the area of stem cell transplant. He holds key positions with several transplant organizations, including the International Bone Marrow Transplant Registry Executive Committee, the Blood and Marrow Transplant Clinical Trials Network (BMTCTN) Steering Committee, the National Marrow Donor Program Board of Directors, and the Clinical Advisory Board of the website Managing Myeloma. He is the chair of the BMTCTN and past chair of Center for International Blood and Marrow Transplant Research. Dr. Giralt has published over 400 articles and abstracts in peer-reviewed literature and has written chapters for several books.